🇺🇸 FDA

Company profile · Sponsor

Inhibrx

Inhibrx Biosciences

INBX · NYSE biotech LA JOLLA, CA, USA
Pipeline
10
Drugs
0
Patents
8

Quick answer

Inhibrx (INBX) is a biotech company. headquartered in LA JOLLA, CA, USA. listed on NYSE. NovaPharmaNews links 10 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker INBX
Exchange NYSE
Company type biotech
Headquarters LA JOLLA, CA, USA
SEC CIK 0002007919

Pipeline (10)

Search pipeline →

  1. Commercially available 0,9 % sterile saline solution with marketing authorization will be utilized as the placebo., KEYTRUDA 25 mg/mL concentrate for solution for infusion, INBRX-106, INBRX-106

    Inhibrx

    Head and Neck Squamous Cell Carcinoma

    phase 3 small molecule active

    1 trial

  2. INBRX-106

    Inhibrx

    Head and Neck Squamous Cell Carcinoma (HNSCC)

    phase 3 small molecule active

    1 trial

  3. ACETYLCYSTEINE , DEXAMETHASONE , DIPHENHYDRAMINE , GLUCOSE

    Inhibrx

    Unresectable or metastatic conventional chondrosarcoma

    phase 2 small molecule active

    1 trial

  4. Campto 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Campto 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, DEXAMETHASONE , Temodal 180 mg hard capsules, Temodal 5 mg hard capsules, Temodal 140 mg hard capsules, Temodal 100 mg hard capsules, Campto 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Temodal 20 mg hard capsules, Temodal 250 mg hard capsules

    Inhibrx

    Advanced or metastatic solid tumors

    phase 2 small molecule active

    1 trial

  5. INBRX-106 - Hexavalent OX40 agonist antibody

    Inhibrx

    Solid Tumor

    phase 2 small molecule active

    1 trial

  6. INBRX-109

    Inhibrx

    Conventional Chondrosarcoma

    phase 2 small molecule active

    1 trial

  7. Pembrolizumab

    Inhibrx

    Triple Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  8. INBRX-101/rhAAT-Fc

    Inhibrx

    Alpha-1 Antitrypsin Deficiency

    phase 1 small molecule completed

    1 trial

  9. INBRX-105 - PDL1x41BB antibody

    Inhibrx

    Metastatic Solid Tumors

    phase 1 small molecule terminated

    1 trial

  10. INBRX-109

    Inhibrx

    Ewing Sarcoma

    phase 1 small molecule active

    1 trial

Patents (8)

Search patents →

  1. US 12365728

    DLL3 single domain antibodies and therapeutic compositions thereof

    Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12331126

    OX40-binding polypeptides and uses thereof

    Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12331132

    Multispecific polypeptide constructs having constrained CD3 binding and related methods and uses

    Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12227584

    Multivalent and multispecific OX40-binding fusion proteins

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12187804

    Multivalent and multispecific 41BB-binding proteins

    Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12084502

    CD33-binding polypeptides and uses thereof

    Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12043667

    CLEC12a binding polypeptides and uses thereof

    Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12012459

    OX40-binding polypeptides and uses thereof

    Expires Mon Jun 13 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Inhibrx?

Inhibrx (INBX) is a biotech company. headquartered in LA JOLLA, CA, USA. listed on NYSE. NovaPharmaNews links 10 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does Inhibrx sponsor?

We track 10 ClinicalTrials.gov-linked programs for Inhibrx, including Commercially available 0,9 % sterile saline solution with marketing authorization will be utilized as the placebo., KEYTRUDA 25 mg/mL concentrate for solution for infusion, INBRX-106, INBRX-106 and 9 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Inhibrx company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.